These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37792951)

  • 1. History of primary-series and booster vaccination and protection against Omicron reinfection.
    Chemaitelly H; Ayoub HH; Tang P; Coyle PV; Yassine HM; Al Thani AA; Al-Khatib HA; Hasan MR; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R; Abu-Raddad LJ
    Sci Adv; 2023 Oct; 9(40):eadh0761. PubMed ID: 37792951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
    Nielsen KF; Moustsen-Helms IR; Schelde AB; Gram MA; Emborg HD; Nielsen J; Hansen CH; Andersen MA; Meaidi M; Wohlfahrt J; Valentiner-Branth P
    PLoS Med; 2022 Nov; 19(11):e1004037. PubMed ID: 36413551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.
    Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN
    Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study.
    Carazo S; Skowronski DM; Brisson M; Barkati S; Sauvageau C; Brousseau N; Gilca R; Fafard J; Talbot D; Ouakki M; Gilca V; Carignan A; Deceuninck G; De Wals P; De Serres G
    Lancet Infect Dis; 2023 Jan; 23(1):45-55. PubMed ID: 36152671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA.1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A test-negative case-control analysis.
    Lind ML; Robertson AJ; Silva J; Warner F; Coppi AC; Price N; Duckwall C; Sosensky P; Di Giuseppe EC; Borg R; Fofana MO; Ranzani OT; Dean NE; Andrews JR; Croda J; Iwasaki A; Cummings DAT; Ko AI; Hitchings MDT; Schulz WL
    PLoS Med; 2022 Dec; 19(12):e1004136. PubMed ID: 36454733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
    Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
    Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of SARS-CoV-2 reinfection by vaccination status, predominant variant and time from prior infection: a cohort study, Reggio Emilia province, Italy, February 2020 to February 2022.
    Vicentini M; Venturelli F; Mancuso P; Bisaccia E; Zerbini A; Massari M; Cossarizza A; De Biasi S; Pezzotti P; Bedeschi E; Giorgi Rossi P; ;
    Euro Surveill; 2023 Mar; 28(13):. PubMed ID: 36995374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duration of immune protection of SARS-CoV-2 natural infection against reinfection.
    Chemaitelly H; Nagelkerke N; Ayoub HH; Coyle P; Tang P; Yassine HM; Al-Khatib HA; Smatti MK; Hasan MR; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R; Abu-Raddad LJ
    J Travel Med; 2022 Dec; 29(8):. PubMed ID: 36179099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection Against the Omicron Variant Offered by Previous Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Retrospective Cohort Study.
    Rothberg MB; Kim P; Shrestha NK; Kojima L; Tereshchenko LG
    Clin Infect Dis; 2023 Feb; 76(3):e142-e147. PubMed ID: 35867678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Booster vaccination protection against SARS-CoV-2 infections in young adults during an Omicron BA.1-predominant period: A retrospective cohort study.
    Wan J; Cazer CL; Clarkberg ME; Henderson SG; Lee SE; Meredith GR; Osman M; Shmoys DB; Frazier PI
    PLoS Med; 2023 Jan; 20(1):e1004153. PubMed ID: 36626376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.
    Zheng H; Wu S; Chen W; Cai S; Zhan M; Chen C; Lin J; Xie Z; Ou J; Ye W
    Front Public Health; 2024; 12():1457266. PubMed ID: 39253287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression.
    Bobrovitz N; Ware H; Ma X; Li Z; Hosseini R; Cao C; Selemon A; Whelan M; Premji Z; Issa H; Cheng B; Abu Raddad LJ; Buckeridge DL; Van Kerkhove MD; Piechotta V; Higdon MM; Wilder-Smith A; Bergeri I; Feikin DR; Arora RK; Patel MK; Subissi L
    Lancet Infect Dis; 2023 May; 23(5):556-567. PubMed ID: 36681084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Omicron Variant Reinfection Risk among Individuals with a Previous SARS-CoV-2 Infection within One Year in Shanghai, China: A Cross-Sectional Study.
    Ye C; Zhang G; Zhang A; Xin H; Wu K; Li Z; Jia Y; Hao L; Xue C; Wang Y; Xu H; Zhu W; Zhou Y
    Vaccines (Basel); 2023 Jun; 11(7):. PubMed ID: 37514962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Waning natural and vaccine-induced immunity leading to reinfection with SARS-CoV-2 Omicron variant.
    Shete AM; Patil DY; Sahay RR; Sapkal GN; Deshpande GR; Yadav PD
    Hum Vaccin Immunother; 2022 Nov; 18(6):2127289. PubMed ID: 36170667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 Reinfections in Health-Care Workers, 1 March 2020-31 January 2023.
    Cegolon L; Magnano G; Negro C; Larese Filon F;
    Viruses; 2023 Jul; 15(7):. PubMed ID: 37515237
    [No Abstract]   [Full Text] [Related]  

  • 16. Role of previous infection with SARS-CoV-2 in protecting against omicron reinfections and severe complications of COVID-19 compared to pre-omicron variants: a systematic review.
    Arabi M; Al-Najjar Y; Sharma O; Kamal I; Javed A; Gohil HS; Paul P; Al-Khalifa AM; Laws S; Zakaria D
    BMC Infect Dis; 2023 Jun; 23(1):432. PubMed ID: 37365490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and severity of SARS-CoV-2 reinfection, a multicenter cohort study in Shanghai, China.
    Yu W; Guo Y; Hu T; Liu Y; Fan Q; Guo L; Zheng B; Kong Y; Zhu H; Yu J; Chen S; Zhang Y; Wang J; Li F; Yang F; Wang Y; Zhu Y; Huang Y; Shen Z; Ruan Y; Mao R; Zhang J
    J Med Virol; 2023 Aug; 95(8):e28997. PubMed ID: 37537950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland-A multicentre cohort study.
    Babouee Flury B; Güsewell S; Egger T; Leal O; Brucher A; Lemmenmeier E; Meier Kleeb D; Möller JC; Rieder P; Rütti M; Schmid HR; Stocker R; Vuichard-Gysin D; Wiggli B; Besold U; McGeer A; Risch L; Friedl A; Schlegel M; Kuster SP; Kahlert CR; Kohler P;
    PLoS Med; 2022 Nov; 19(11):e1004125. PubMed ID: 36342956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study.
    Mok CKP; Chen C; Zhao S; Sun Y; Yiu K; Chan TO; Lai HL; Lai KC; Lau KM; Ling KC; Chan KKP; Ng SS; Ko FW; Peiris M; Hui DS
    Lancet Microbe; 2023 Jun; 4(6):e418-e430. PubMed ID: 37086735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort.
    Itamochi M; Yazawa S; Inasaki N; Saga Y; Yamazaki E; Shimada T; Tamura K; Maenishi E; Isobe J; Nakamura M; Takaoka M; Sasajima H; Kawashiri C; Tani H; Oishi K
    Vaccine; 2023 Mar; 41(13):2234-2242. PubMed ID: 36858871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.